MNKD · MannKind Corporation

The thesis

MannKind Corporation's shift from inhaled insulin to Furoscix and royalty income has not lifted the shares, which closed at $3.20 on 22 October 2026, and the third-quarter report decides whether it will. The tests are Furoscix sales above the $22.2 million and Tyvaso DPI (dry-powder inhaler) royalties of at least the $32.4 million reported for the second quarter on 5 August 2026. Those two thresholds are research markers, not company guidance.

The shares sit 48.5% below the 52-week high of $6.21 and fell 19.0% over the three months to 22 October 2026 (adjusted daily closes). Analyst support widened this week while the price kept falling: Chardan Capital initiated coverage with a Buy rating and a $10 price target on 19 October 2026, and Cantor Fitzgerald reiterated Overweight with an $8 target on 20 October 2026. The narrative is maturing: the 23 July 2026 ReadyFlow autoinjector approval and the 5 August 2026 results are public, and the newest news is analyst coverage and clinical data, not new revenue.

Bullish and bearish views on MannKind Corporation

The bull case on MannKind Corporation (MNKD), in brief: Furoscix has a measurable sales test. The bear case: The shares keep falling through analyst upgrades.

Bull case

• Furoscix has a measurable sales test. MannKind reported $22.2 million of Furoscix sales for the second quarter on 5 August 2026, and the Food and Drug Administration approved the ReadyFlow autoinjector on 23 July 2026. Third-quarter sales above $22.2 million would support the expansion case.
• Royalties at or above $32.4 million would keep that stream steady.
• New analysts are bullish on the stock. Chardan initiated at Buy with a $10 target on 19 October 2026, and Cantor Fitzgerald maintained an $8 target on 20 October 2026 and 21 October 2026. Both targets sit well above the $3.20 close of 22 October 2026.
• Clinical data support the device. MannKind reported on 12 October 2026 that new analyses at the Heart Failure Society of America (HFSA) 2026 meeting showed the under-10-second ReadyFlow autoinjector produced urine output comparable to intravenous furosemide.
• The platform gained another license. The 9 September 2026 Rose Pharma agreement covers an investigational inhaled GLP-1 therapy for weight management, with an equity interest and potential royalties. No financial terms were disclosed.

Bear case

• The shares keep falling through analyst upgrades. The close of $3.20 on 22 October 2026 is below the $3.29 close of 9 October 2026 and the $3.34 close of 25 September 2026. The 14-day relative strength index (RSI) was 28.6, a reading usually described as oversold, so selling has been persistent.
• Analyst views are far apart. Truist Securities cut its target to $5 on 7 October 2026 while keeping Buy; Cantor's target is $8 and Chardan's is $10. A spread of that width shows no agreement on what the shares are worth.
• Growth costs more than it earns. The second-quarter 2026 net loss was $19.0 million, against $0.7 million of net income a year earlier. Afrezza sales fell 7% year over year to $17.0 million (company results, 5 August 2026).
• The balance sheet is thin. At 30 June 2026 MannKind reported $319.1 million of term-loan debt, $111 million of cash and investments, and a $67.2 million stockholders' deficit.

Price setup

The last adjusted daily close was $3.20 on 22 October 2026. That is 48.5% below the 52-week high of $6.21 and 6.7% above the round-number $3.00 level used as the invalidation close. The shares have made lower closes since the previous note's $3.29 on 9 October 2026.

Crowding evidence is limited. No SEC Form 4 insider filings or new share issuance appear in filings since the last note, and no measure of heavy retail attention is available. The observable pressure points are the resale registration and the quarterly report expected in early November.

Catalysts, next 30 days

• Rolling: Form 4 and resale filings. Filings that show sales of the 12,853,470 registered shares would add supply while the company reports losses.

Elapsed catalysts

• ~5 November 2026, est.: third-quarter 2026 earnings report. MannKind has not confirmed the date. It reported the second quarter on 5 August 2026 and held its third-quarter 2025 call on 5 November 2025, so early November is the likely window. The report shows Furoscix sales against $22.2 million and Tyvaso DPI royalties against $32.4 million. (passed 1d ago)

What would change the view

The rebuilding case breaks if third-quarter Furoscix sales come in at or below $22.2 million, or if Tyvaso DPI royalties fall below $32.4 million. Either result would show the commercial pivot has stalled after the ReadyFlow approval. A daily close below $3.00 would confirm the market has rejected the case before the report.

The case strengthens if both figures clear the second-quarter levels and the shares recover above the $3.34 close of 25 September 2026. Further target cuts of the kind Truist made on 7 October 2026 would count against it. Evidence of resale-stock sales alongside another net loss would also weaken it.

What it trades with

MannKind trades on its own commercial results more than on a sector move. Tyvaso DPI royalties tie it to the sales of its partner's pulmonary hypertension product, and Furoscix ties it to heart-failure drug uptake. The Rose Pharma license links it loosely to interest in inhaled weight-management drugs, but no revenue from that agreement has been disclosed.